相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2009)
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan
C. I. Ripamonti et al.
ANNALS OF ONCOLOGY (2009)
Vertebroplasty in multiple myeloma: Outcomes in a large patient series
R. J. McDonald et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2008)
Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
Ashraf Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
C. Jakob et al.
LEUKEMIA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
M. Aapro et al.
ANNALS OF ONCOLOGY (2008)
Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome
N. Yarom et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients
Maurizio Zangari et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function
Raoul Bergner et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
A systematic review of persistence and compliance with bisphosphonates for osteoporosis
J. A. Cramer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma
Amir H. Montazerit et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma
A. Corso et al.
LEUKEMIA (2007)
An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
K. Cocks et al.
EUROPEAN JOURNAL OF CANCER (2007)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A. Kyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Osteonecrosis of the jaws associated with use of risedronate: Report of 2 new cases
John K. Brooks et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2007)
Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006
Richard Weitzman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma
Cindy Baulch-Brown et al.
LEUKEMIA RESEARCH (2007)
Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia
Tony Mavrokokki et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2007)
Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: A role for vascular endothelial cell growth factor and osteopontin
Ybichi Tanaka et al.
CLINICAL CANCER RESEARCH (2007)
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
Robert E. Coleman et al.
LANCET ONCOLOGY (2007)
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
E. Terpos et al.
LEUKEMIA (2007)
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma
Allan Lipton et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
PET/CT and MR imaging in myeloma
Michael E. Mulligan et al.
SKELETAL RADIOLOGY (2007)
The use of bisphosphonates in elderly cancer patients
Cesare Gridelli
ONCOLOGIST (2007)
Managing metastatic bone pain: The role of bisphosphonates
Julie Gralow et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2007)
Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement
Brian G. M. Durie
MAYO CLINIC PROCEEDINGS (2007)
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
Nicola Giuliani et al.
BLOOD (2006)
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Evangelos Terpos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate
Deborah T. Gold et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Proteasome inhibition as a new therapeutic principle in hematological malignancies
Constantine S. Mitsiades et al.
CURRENT DRUG TARGETS (2006)
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients
Kostas Zervas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Ulrike Heider et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma
Martha Q. Lacy et al.
MAYO CLINIC PROCEEDINGS (2006)
Bone markers in multiple myeloma
Ulrike Heider et al.
EUROPEAN JOURNAL OF CANCER (2006)
The role of anatomic and functional staging in myeloma: Description of Durie/Salmon PLUS staging system
Brian G. M. Durie
EUROPEAN JOURNAL OF CANCER (2006)
Systematic review: Bisphosphonates and osteonecrosis of the jaws
Sook-Bin Woo et al.
ANNALS OF INTERNAL MEDICINE (2006)
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma
P Tosi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases
JE Dunford et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis
T Hansen et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2006)
Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors
A Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bone complications in multiple myeloma
James R. Berenson et al.
CANCER BIOLOGY & THERAPY (2006)
Management of the adverse effects associated with intravenous bisphosphonates
T. Tanvetyanon et al.
ANNALS OF ONCOLOGY (2006)
Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy - Strategies for prevention and early recognition
MD Melo et al.
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION (2005)
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
A Bamias et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
E Terpos et al.
LEUKEMIA (2005)
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
T Oshima et al.
BLOOD (2005)
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
N Giuliani et al.
BLOOD (2005)
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers
F Fulfaro et al.
JOURNAL OF CHEMOTHERAPY (2005)
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
LA Ehrlich et al.
BLOOD (2005)
Myeloma bone disease: pathophysiology and management
E Terpos et al.
ANNALS OF ONCOLOGY (2005)
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
RE Coleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Role of MRI for the diagnosis and prognosis of multiple myeloma
A Baur-Melnyk et al.
EUROPEAN JOURNAL OF RADIOLOGY (2005)
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration
A Wardley et al.
BRITISH JOURNAL OF CANCER (2005)
The role of markers of bone remodeling in multiple myeloma
E Terpos et al.
BLOOD REVIEWS (2005)
Value of FDG PET in the assessment of patients with multiple myeloma
MA Bredella et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2005)
Clodronate in the prevention and treatment of skeletal metastasis
J Gulley et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma
JL Harrouseau et al.
ANNALS OF ONCOLOGY (2005)
Lesson of the week - Severe hypocalcaemia after being given intravenous bisphosphonate
R Peter et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid
J Kuroda et al.
CANCER SCIENCE (2004)
Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells
F Silvestris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy
M Pecherstorfer et al.
SUPPORTIVE CARE IN CANCER (2004)
Zoledronic acid - A review of its use in patients with advanced cancer
CM Perry et al.
DRUGS (2004)
Transforming growth factor β receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment
T Hayashi et al.
CLINICAL CANCER RESEARCH (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The high rate of bone resorption in multiple myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK ligand expression
S Roux et al.
LEUKEMIA & LYMPHOMA (2004)
Bisphosphonate infusions: patient preference, safety and clinic use
B Chern et al.
SUPPORTIVE CARE IN CANCER (2004)
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy
CL Vogel et al.
ONCOLOGIST (2004)
Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases
SL Ruggiero et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2004)
Bone remodelation markers are useful in the management of monoclonal gammopathies
JM Hernandez et al.
HEMATOLOGY JOURNAL (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma
E Terpos et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
RE Marx
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group
LS Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Multiple myeloma biology: lessons from the 5TMM models
K Vanderkerken et al.
IMMUNOLOGICAL REVIEWS (2003)
γδ T cells for immune therapy of patients with lymphoid malignancies
M Wilhelm et al.
BLOOD (2003)
Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease
F Silvestris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Toxic acute tubular necrosis following treatment with zoledronate (Zometa)
GS Markowitz et al.
KIDNEY INTERNATIONAL (2003)
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival
PI Croucher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
New insights into the pathophysiology and management of bone disease in multiple myeloma
E Terpos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta(2)-microglobulin in multiple myeloma
E Terpos et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Efficacy of zoledronic acid and pamidronate in breast cancer patients: A comparative analysis of Randomized phase III trials
RE Coleman
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
JR Berenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect
A Martín et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma
C Jakob et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2002)
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
HD Menssen et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Nephrotic syndrome after treatment with pamidronate
GS Markowitz et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma
S Dudeney et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Anti-tumor activity of pamidronate in human multiple myeloma
H Kondo et al.
LEUKEMIA & LYMPHOMA (2002)
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
S Yaccoby et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Complementary and alternative therapies for advanced prostate cancer
MR Smith
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2001)
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
EV McCloskey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment
E Terpos et al.
CALCIFIED TISSUE INTERNATIONAL (2001)
Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma
JC Cruz et al.
EXPERIMENTAL HEMATOLOGY (2001)
Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma
E Terpos et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma
CM Shipman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines
P Tassone et al.
LEUKEMIA (2000)
An unusual coma after therapy for bone pain
S Mercadante et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2000)
分享论文
